1-3 of 3
Sean Landrette
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, PhD, Jeff Grotzke, PhD, Sophia Gayle, PhD, Marylens Hernandez, PhD, Stephanie Halene, MD, Peter R Young, PhD, Langdon L Miller, MD, Tian Xu, PhD, Jonathan Rothberg, PhD, Henri Lichenstein, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2664.
https://doi.org/10.1182/blood-2019-125770
Published: 2019
Journal Articles

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, MD, Catherine S Diefenbach, MD, Nehal Lakhani, MD PhD, Sarah C Rutherford, MD, Marshall T Schreeder, MD, Stephen M Ansell, MD PhD, Taimur Sher, MD, David M Aboulafia, MD, Jonathon B Cohen, MDMS, Darrell Nix, BS, PhD, Sean Landrette, PhD, Kate Flanders, BS, Langdon L Miller, MD, Henri Lichenstein, PhD, Jeremy S. Abramson, MD MMSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4119.
https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119
Published: 2017
Journal Articles

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Journal: Blood
Blood (2017) 129 (13): 1768–1778.
https://doi.org/10.1182/blood-2016-09-736892
Published: 2017
Includes: Supplemental data